Literature DB >> 12498014

Avinza Elan.

Marilyn R Semenchuk1.   

Abstract

Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 h. It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806].

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498014

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  3 in total

Review 1.  Recent advances in clinical use of opioids.

Authors:  Eric Chevlen
Journal:  Curr Pain Headache Rep       Date:  2004-06

2.  Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.

Authors:  Murad R Melhem; Christopher M Rubino; Stephen J Farr; Cynthia Y Robinson
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

3.  Extended-release morphine sulfate in treatment of severe acute and chronic pain.

Authors:  Robert J Balch; Andrea Trescot
Journal:  J Pain Res       Date:  2010-09-21       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.